Evotec completes Aptuit acquisition

By Melissa Fassbender contact

- Last updated on GMT

Evotec entered into a definitive agreement to acquire Aptuit on July 30, 2017. (Image: iStock/daizuoxin)
Evotec entered into a definitive agreement to acquire Aptuit on July 30, 2017. (Image: iStock/daizuoxin)

Related tags: Completeness

Evotec has completed its previously announced acquisition of Aptuit and has updated its financial targets for the year.

As Outsourcing-Pharma.com reported​, the acquisition enables Evotec to provide its customers with “an even better and more complete translation process from the discovery stage to the clinical manufacturing​,” according to Dr. Werner Lanthaler, Evotec CEO.

"We are very happy that the closing was faster than originally expected. This now brings a one-stop-solution together for our partners from target to IND and high end-CMC,​" Lanthaler told us.

Evotec purchased Aptuit from the private equity firm Welsh, Carson, Anderson & Stowe for a total consideration of approximately $300m (€256m).

Guidance update

Following the transaction’s closing, Evotec has also updated its financial targets for 2017.

According to the company, total group revenues are expected to increase by more than 40% compared to 2016 at which time it was approximately $192.59m (€164.5m).

Additionally, adjusted group EBITDA is expected to improve from $42.38m (€36.2m) in 2016 by more than 50%. Group R&D expenses are expected to be approximately $23.41m (€20m).

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars